Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
favezelimab + vibostolimab
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**favezelimab + vibostolimab** is an investigational combination therapy comprising two monoclonal antibodies: favezelimab (an anti-LAG-3 antibody) and vibostolimab (an anti-TIGIT antibody). The combination was developed for use as an immunotherapy in cancer, aiming to enhance immune responses against tumors by blocking inhibitory immune checkpoints. Both antibodies target distinct checkpoint proteins (LAG-3 and TIGIT), which suppress anti-tumor T cell activity. By inhibiting these proteins, the drugs are designed to improve the immune system's ability to detect and destroy cancer cells. Development was led by Merck for several cancer indications, but has been discontinued following multiple phase 3 clinical trial failures in non-small cell lung cancer and lymphoma[1][3][5][6][7].
- Other names
- favezelimab + vibostolimab
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on favezelimab + vibostolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on favezelimab + vibostolimab.